|
1
|
Wilcox RA: Cutaneous T-cell lymphoma: 2016
update on diagnosis, risk-stratification, and management. Am J
Hematol. 91:151–165. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Goyal A, O'Leary D, Goyal K, Rubin N,
Bohjanen K, Hordinsky M, Chen ST, Pongas G, Duncan LM and Lazaryan
A: Increased risk of second primary hematologic and solid
malignancies in patients with mycosis fungoides: A surveillance,
epidemiology, and end results analysis. J Am Acad Dermatol.
83:404–411. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang Y, Wang Y, Yu R, Huang Y, Su M, Xiao
C, Martinka M, Dutz JP, Zhang X, Zheng Z and Zhou Y: Molecular
markers of early-stage mycosis fungoides. J Invest Dermatol.
132:1698–1706. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lansigan F, Choi J and Foss FM: Cutaneous
T-cell lymphoma. Hematol Oncol Clin North Am. 22979–996. (x)2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Prince HM, Whittaker S and Hoppe RT: How I
treat mycosis fungoides and Sezary syndrome. Blood. 114:4337–4353.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang C, Richon V, Ni X, Talpur R and
Duvic M: Selective induction of apoptosis by histone deacetylase
inhibitor SAHA in cutaneous T-cell lymphoma cells: Relevance to
mechanism of therapeutic action. J Invest Dermatol. 125:1045–1052.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Willemze R, Jaffe ES, Burg G, Cerroni L,
Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL,
Duncan LM, et al: WHO-EORTC classification for cutaneous lymphomas.
Blood. 105:3768–3785. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hock H, Hamblen MJ, Rooke HM, Traver D,
Bronson RT, Cameron S and Orkin SH: Intrinsic requirement for zinc
finger transcription factor Gfi-1 in neutrophil differentiation.
Immunity. 18:109–120. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yucel R, Karsunky H, Klein-Hitpass L and
Moroy T: The transcriptional repressor Gfi1 affects development of
early, uncommitted c-Kit+ T cell progenitors and CD4/CD8 lineage
decision in the thymus. J Exp Med. 197:831–844. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
van der Meer LT, Jansen JH and van der
Reijden BA: Gfi1 and Gfi1b: Key regulators of hematopoiesis.
Leukemia. 24:1834–1843. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhu J, Jankovic D, Grinberg A, Guo L and
Paul WE: Gfi-1 plays an important role in IL-2-mediated Th2 cell
expansion. Proc Natl Acad Sci USA. 103:18214–18219. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rodel B, Tavassoli K, Karsunky H, Schmidt
T, Bachmann M, Schaper F, Heinrich P, Shuai K, Elsässer HP and
Möröy T: The zinc finger protein Gfi-1 can enhance STAT3 signaling
by interacting with the STAT3 inhibitor PIAS3. EMBO J.
19:5845–5855. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kazanjian A, Gross EA and Grimes HL: The
growth factor independence-1 transcription factor: New functions
and new insights. Crit Rev Oncol Hematol. 59:85–97. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou LL, Zhao Y, Ringrose A, DeGeer D,
Kennah E, Lin AE, Sheng G, Li XJ, Turhan A and Jiang X: AHI-1
interacts with BCR-ABL and modulates BCR-ABL transforming activity
and imatinib response of CML stem/progenitor cells. J Exp Med.
205:2657–2671. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang Y, Su M, Zhou LL, Tu P, Zhang X,
Jiang X and Zhou Y: Deficiency of SATB1 expression in Sezary cells
causes apoptosis resistance by regulating FasL/CD95L transcription.
Blood. 117:3826–3835. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Su MW, Dorocicz I, Dragowska WH, Ho V, Li
G, Voss N, Gascoyne R and Zhou Y: Aberrant expression of T-plastin
in Sezary cells. Cancer Res. 63:7122–7127. 2003.PubMed/NCBI
|
|
17
|
Gu X, Wang Y, Zhang G, Li W and Tu P:
Aberrant expression of BCL11B in mycosis fungoides and its
potential role in interferon-induced apoptosis. J Dermatol.
40:596–605. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Campbell JJ, Clark RA, Watanabe R and
Kupper TS: Sezary syndrome and mycosis fungoides arise from
distinct T-cell subsets: A biologic rationale for their distinct
clinical behaviors. Blood. 116:767–771. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
van Doorn R, van Kester MS, Dijkman R,
Vermeer MH, Mulder AA, Szuhai K, Knijnenburg J, Boer JM, Willemze R
and Tensen CP: Oncogenomic analysis of mycosis fungoides reveals
major differences with Sezary syndrome. Blood. 113:127–136. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hwang ST, Janik JE, Jaffe ES and Wilson
WH: Mycosis fungoides and Sezary syndrome. Lancet. 371:945–957.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dummer R, Asagoe K, Cozzio A, Burg G,
Doebbeling U, Golling P, Fujii K and Urosevic M: Recent advances in
cutaneous lymphomas. J Dermatol Sci. 48:157–167. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Y, Gu X, Li W, Zhang Q and Zhang C:
PAK1 overexpression promotes cell proliferation in cutaneous T cell
lymphoma via suppression of PUMA and p21. J Dermatol Sci. 90:60–67.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang Y, Litvinov IV, Wang Y, Su MW, Tu P,
Jiang X, Kupper TS, Dutz JP, Sasseville D and Zhou Y: Thymocyte
selection-associated high mobility group box gene (TOX) is
aberrantly over-expressed in mycosis fungoides and correlates with
poor prognosis. Oncotarget. 5:4418–4425. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ringrose A, Zhou Y, Pang E, Zhou L, Lin
AE, Sheng G, Li XJ, Weng A, Su MW, Pittelkow MR and Jiang X:
Evidence for an oncogenic role of AHI-1 in Sezary syndrome, a
leukemic variant of human cutaneous T-cell lymphomas. Leukemia.
20:1593–1601. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fu W, Yi S, Qiu L, Sun J, Tu P and Wang Y:
BCL11B-Mediated epigenetic repression is a crucial target for
histone deacetylase inhibitors in cutaneous T-Cell lymphoma. J
Invest Dermatol. 137:1523–1532. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Frei GM, Kremer M, Hanschmann KM, Krause
S, Albeck M, Sredni B and Schnierle BS: Antitumour effects in
mycosis fungoides of the immunomodulatory, tellurium-based
compound, AS101. Br J Dermatol. 158:578–586. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Grimes HL, Chan TO, Zweidler-McKay PA,
Tong B and Tsichlis PN: The Gfi-1 proto-oncoprotein contains a
novel transcriptional repressor domain, SNAG, and inhibits G1
arrest induced by interleukin-2 withdrawal. Mol Cell Biol.
16:6263–6272. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Duan Z, Zarebski A, Montoya-Durango D,
Grimes HL and Horwitz M: Gfi1 coordinates epigenetic repression of
p21Cip/WAF1 by recruitment of histone lysine methyltransferase G9a
and histone deacetylase 1. Mol Cell Biol. 25:10338–10351. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mandal M, Bandyopadhyay D, Goepfert TM and
Kumar R: Interferon-induces expression of cyclin-dependent
kinase-inhibitors p21WAF1 and p27Kip1 that prevent activation of
cyclin-dependent kinase by CDK-activating kinase (CAK). Oncogene.
16:217–225. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Abbas T, Jha S, Sherman NE and Dutta A:
Autocatalytic phosphorylation of CDK2 at the activating Thr160.
Cell Cycle. 6:843–852. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Martin-Caballero J, Flores JM,
Garcia-Palencia P and Serrano M: Tumor susceptibility of
p21(Waf1/Cip1)-deficient mice. Cancer Res. 61:6234–6238.
2001.PubMed/NCBI
|
|
32
|
Shiohara M, el-Deiry WS, Wada M, Nakamaki
T, Takeuchi S, Yang R, Chen DL, Vogelstein B and Koeffler HP:
Absence of WAF1 mutations in a variety of human malignancies.
Blood. 84:3781–3784. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Grimes HL, Gilks CB, Chan TO, Porter S and
Tsichlis PN: The Gfi-1 protooncoprotein represses Bax expression
and inhibits T-cell death. Proc Natl Acad Sci USA. 93:14569–14573.
1996. View Article : Google Scholar : PubMed/NCBI
|
